There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Research (NASDAQ:ARWR) and Bausch Health Companies Inc (NYSE:BHC) with bullish sentiments.
Arrowhead Research (ARWR)
In a report released today, Maury Raycroft from Jefferies reiterated a Buy rating on Arrowhead Research, with a price target of $20. The company’s shares opened today at $15.44, close to its 52-week high of $17.50.
According to TipRanks.com, Raycroft is a 5-star analyst with an average return of 27.9% and a 53.8% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Research with a $19.83 average price target, implying a 28.4% upside from current levels. In a report issued on August 1, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
Bausch Health Companies Inc (BHC)
In a report released today, David Steinberg from Jefferies reiterated a Buy rating on Bausch Health Companies Inc, with a price target of $27. The company’s shares opened today at $23.58.
According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 10.7% and a 50.8% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Pacira Pharmaceuticals, and Menlo Therapeutics Inc.
Currently, the analyst consensus on Bausch Health Companies Inc is a Hold with an average price target of $23.45, representing a -0.6% downside. In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $31 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
